Clinical Trials Sponsored by Roche-Genentech

Total 4534 results

Genentech, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)

COVID-19 Pneumonia

United States, Peru, Kenya, Mexico, Brazil, South Africa
Genentech, Inc.

Completed

A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma (AQUA)

Allergic Asthma
Genentech, Inc.

Terminated

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

Chondrosarcoma

United States, Australia
Genentech, Inc.

Completed

A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Metastatic Colorectal Cancer
Genentech, Inc.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy

Geographic Atrophy
Genentech, Inc.

Completed

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma

United States, Australia
Genentech, Inc.

Completed

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

Belgium, Australia, Denmark, Norway
Genentech, Inc.

Completed

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Gastric Cancer

Spain, Korea, Republic of, Italy, United Kingdom, United States, Singapore, Taiwan, Germany, Malaysia, Hong Kong, France
Genentech, Inc.

Completed

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

Breast Cancer

United States, Korea, Republic of
Genentech, Inc.

Completed

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Metastatic Breast Cancer

United States
Genentech, Inc.

Terminated

A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy (HydranGea)

Breast Cancer

United States, Spain, United Kingdom, Germany, Korea, Republic of, Australia
Genentech, Inc.

Completed

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors (LOTUS)

Breast Neoplasms

United States, Spain, Korea, Republic of, Taiwan, Italy, Singapore, France, Belgium
Genentech, Inc.

Terminated

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

Rheumatoid Arthritis

United States
Genentech, Inc.

Completed

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Urticaria

United States, Germany, Canada
Genentech, Inc.

Completed

A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.

Solid Tumor

United Kingdom
Genentech, Inc.

Completed

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

Healthy Volunteers

United States
Genentech, Inc.

Completed

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Netherlands, Canada
Genentech, Inc.

Completed

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States, Korea, Republic of, Serbia, Argentina, Bulgaria, Poland, Ukraine, Colombia, Russian Federation, Brazil, Mexico
Genentech, Inc.

Completed

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

Diabetes Mellitus, Type 2 | Non-Alcoholic Fatty Liver Disease

United States, Canada
Genentech, Inc.

Completed

A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects

Healthy Volunteers

United States
Genentech, Inc.

Completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, Canada, France, Italy, Germany, Netherlands
Genentech, Inc.

Completed

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Genentech, Inc.

Completed

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Alzheimer's Disease

United States
Genentech, Inc.

Completed

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, Canada
Genentech, Inc.

Completed

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Geographic Atrophy

United States
Genentech, Inc.

Terminated

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

Urothelial Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Belgium
Genentech, Inc.

Completed

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Influenza A

United States, Spain, Korea, Republic of, United Kingdom, Canada, New Zealand, South Africa
Genentech, Inc.

Completed

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Breast Cancer

United States
Genentech, Inc.

Completed

A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Pancreatic Neoplasms | Ovarian Neoplasms

United States
Genentech, Inc.

Completed

A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection

Influenza

Spain, United Kingdom, Korea, Republic of, Belgium, Czechia, Canada, Netherlands, Hong Kong, New Zealand, Peru, Germany, France, Israel, Hungary, South Africa, Sweden, Mexico, Taiwan, Brazil, Bulgaria, Chile, Italy, Poland, Russian Federation and more
Genentech, Inc.

Completed

A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumor

United States, France
Genentech, Inc.

Approved for marketing

An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

Hemophilia A

United States
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

Urticaria

United States
Genentech, Inc.

Completed

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

Macular Edema

United States
Genentech, Inc.

No longer available

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis

United States
Genentech, Inc.

Completed

A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Genentech, Inc.

Completed

A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)

Chronic Idiopathic Urticaria
Genentech, Inc.

Completed

A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Solid Cancers
Genentech, Inc.

Completed

Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing (X-PAND)

Allergic Asthma

United States
Genentech, Inc.

Completed

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkins Lymphoma

United States, France, Canada, Netherlands
Genentech, Inc.

Completed

A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) (EXACT)

Asthma
Genentech, Inc.

Completed

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Genentech, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp (SCALP)

Psoriasis
Genentech, Inc.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers

Healthy Volunteer
Genentech, Inc.

Terminated

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Malignant Melanoma

United States
Genentech, Inc.

Completed

A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)

Non-Small Cell Lung Cancer
Genentech, Inc.

Completed

A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed

Ovarian Cancer
Genentech, Inc.

Terminated

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

Cystic Fibrosis

United States
Genentech, Inc.

Completed

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) (RATE)

Non-Hodgkin's Lymphoma
Genentech, Inc.

Completed

A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma

Asthma

3

Subscribe